Objective:To investigate the clinical efficacy and cost-effectiveness of combined hemodialysis(HD)and hemoperfusion(HP)therapy in managing secondary hyperparathyroidism(SHPT)in patients undergoing maintenance hemodial...Objective:To investigate the clinical efficacy and cost-effectiveness of combined hemodialysis(HD)and hemoperfusion(HP)therapy in managing secondary hyperparathyroidism(SHPT)in patients undergoing maintenance hemodialysis(MHD).Methods:A total of 195 patients with MHD and SHPT at Deyang People's Hospital from April 2024 to April 2025 were enrolled.Patients were randomly assigned to a control group receiving standard HD treatment and an experimental group receiving HD combined with HP therapy.The experimental group underwent 1 year of observation(97 cases in the experimental group,98 cases in the control group).During treatment,changes in parathyroid hormone(PTH),serum calcium,serum phosphorus,and inflammatory factors were monitored,along with analysis of treatment-related economic benefits and safety.Results:The experimental group demonstrated significantly better reductions in PTH,serum phosphorus,and inflammatory factors compared to the control group(P<0.05).Although the total treatment cost was slightly higher,the unit cost per therapeutic effect was lower,resulting in a superior cost-effectiveness ratio.Conclusion:Combined HD and HP therapy can significantly improve SHPT-related indicators in MHD patients,demonstrating safety,controllability,and high cost-effectiveness,making it a clinically applicable and recommended treatment option.展开更多
基金supported by the Deyang City Science and Technology Planning Project[Grant Number 2023SZZ010].
文摘Objective:To investigate the clinical efficacy and cost-effectiveness of combined hemodialysis(HD)and hemoperfusion(HP)therapy in managing secondary hyperparathyroidism(SHPT)in patients undergoing maintenance hemodialysis(MHD).Methods:A total of 195 patients with MHD and SHPT at Deyang People's Hospital from April 2024 to April 2025 were enrolled.Patients were randomly assigned to a control group receiving standard HD treatment and an experimental group receiving HD combined with HP therapy.The experimental group underwent 1 year of observation(97 cases in the experimental group,98 cases in the control group).During treatment,changes in parathyroid hormone(PTH),serum calcium,serum phosphorus,and inflammatory factors were monitored,along with analysis of treatment-related economic benefits and safety.Results:The experimental group demonstrated significantly better reductions in PTH,serum phosphorus,and inflammatory factors compared to the control group(P<0.05).Although the total treatment cost was slightly higher,the unit cost per therapeutic effect was lower,resulting in a superior cost-effectiveness ratio.Conclusion:Combined HD and HP therapy can significantly improve SHPT-related indicators in MHD patients,demonstrating safety,controllability,and high cost-effectiveness,making it a clinically applicable and recommended treatment option.
